Varlilumab
As of the edition of 20 October 2026, Varlilumab is an antibody: stopped in 2024; acts on CD27.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 10, 5 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Immune system; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD27 | CD27 antigen | P26842 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 0 | 3 |
| Phase 2 | 6 | 1 | 3 | 2 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Celldex Therapeutics | Lead sponsor of trials | 2011 to now |